Royal Bank Of Canada Verve Therapeutics, Inc. Transaction History

Royal Bank Of Canada

$458 Billion
Q1 2025

A detailed history of Royal Bank Of Canada transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 79,233 shares of VERV stock, worth $881,863. This represents 0.0% of its overall portfolio holdings.

Number of Shares

79,233

Previous 79,845 0.77%

Holding current value

$881,863

Previous $450,000 19.56%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$4.57 - $8.63 $2,796 - $5,281	-612 Reduced 0.77%	79,233 $362,000
Q4 2024 Feb 14, 2025	BUY	$4.5 - $7.19 $194,989 - $311,549	43,331 Added 118.67%	79,845 $450,000
Q3 2024 Nov 14, 2024	BUY	$4.4 - $7.86 $114,505 - $204,548	26,024 Added 248.08%	36,514 $176,000
Q2 2024 Aug 14, 2024	SELL	$4.76 - $12.79 $34,086 - $91,589	-7,161 Reduced 40.57%	10,490 $51,000
Q1 2024 Nov 05, 2024	BUY	$10.81 - $17.96 $77,410 - $128,611	7,161 Added 68.27%	17,651 $234,000
Q1 2024 May 15, 2024	BUY	$10.81 - $17.96 $45,402 - $75,432	4,200 Added 31.22%	17,651 $234,000
Q4 2023 Feb 14, 2024	SELL	$8.84 - $18.7 $56,832 - $120,222	-6,429 Reduced 32.34%	13,451 $187,000
Q3 2023 Nov 14, 2023	BUY	$11.42 - $20.82 $31,987 - $58,316	2,801 Added 16.4%	19,880 $263,000
Q2 2023 Aug 14, 2023	BUY	$13.34 - $19.9 $78,119 - $116,534	5,856 Added 52.18%	17,079 $320,000
Q1 2023 May 15, 2023	SELL	$14.3 - $24.01 $18,590 - $31,213	-1,300 Reduced 10.38%	11,223 $161,000
Q4 2022 Feb 14, 2023	BUY	$17.85 - $40.7 $93,480 - $213,145	5,237 Added 71.88%	12,523 $242,000
Q3 2022 Nov 14, 2022	BUY	$15.63 - $41.49 $96,202 - $255,370	6,155 Added 544.21%	7,286 $250,000
Q2 2022 Aug 15, 2022	SELL	$11.14 - $23.17 $16,041 - $33,364	-1,440 Reduced 56.01%	1,131 $17,000
Q1 2022 May 16, 2022	SELL	$20.92 - $39.36 $93,198 - $175,348	-4,455 Reduced 63.41%	2,571 $58,000
Q4 2021 Feb 14, 2022	SELL	$31.94 - $54.82 $58,577 - $100,539	-1,834 Reduced 20.7%	7,026 $260,000
Q3 2021 Nov 15, 2021	BUY	$46.0 - $73.99 $80,960 - $130,222	1,760 Added 24.79%	8,860 $416,000
Q2 2021 Aug 16, 2021	BUY	$31.92 - $60.25 $226,632 - $427,775	7,100 New	7,100 $428,000

Others Institutions Holding VERV

# of Institutions

201

Shares Held

85.1M

Call Options Held

350K

Put Options Held

186K

View Full List

About Verve Therapeutics, Inc.

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $667M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

More about VERV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.

Account

Royal Bank Of Canada Verve Therapeutics, Inc. Transaction History